# EDGAR Filing Document

**Accession Number:** 0001947867
**File Stem:** 0001493152-23-006947
**Filing Date:** 2023-3
**Character Count:** 10382
**Document Hash:** c2f5b7e690027b342aa99dcea627d1bf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-006947.hdr.sgml**: 20230307

**ACCESSION NUMBER**: 0001493152-23-006947

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20220829

**FILED AS OF DATE**: 20230307

**DATE AS OF CHANGE**: 20230307

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Perlmutter Nathan M
- **CENTRAL INDEX KEY:** 0001947867

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41463
- **FILM NUMBER:** 23714469

**MAIL ADDRESS:**
- **STREET 1:** 28 PARRISH POND LANE
- **CITY:** SOUTHAMPTON
- **STATE:** NY
- **ZIP:** 11968
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** bioAffinity Technologies, Inc.
- **CENTRAL INDEX KEY:** 0001712762
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **IRS NUMBER:** 465211056
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 22211 WEST INTERSTATE-10
- **STREET 2:** SUITE 1206
- **CITY:** SAN ANTONIO
- **STATE:** TX
- **ZIP:** 78257
- **BUSINESS PHONE:** 210-698-5334

**MAIL ADDRESS:**
- **STREET 1:** 22211 WEST INTERSTATE-10
- **STREET 2:** SUITE 1206
- **CITY:** SAN ANTONIO
- **STATE:** TX
- **ZIP:** 78257

## Exhibit 24.1

**Exhibit 24.1**

**POWER OF ATTORNEY**

Know all by these presents, that the undersigned hereby constitutes and appoints each of Wilhelm E. Liebmann and Katherine E. Spiser, or either of them acting singly and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

(1) prepare
 and execute for and on behalf of the undersigned Forms 3, 4, and 5 and Schedules 13D and
 13G in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934, as amended
 (the "Exchange Act"), and the rules promulgated thereunder, as applicable, and
 any other forms or reports the undersigned may be required to file in connection with the
 undersigned's ownership, acquisition, or disposition of securities of bioAffinity Technologies,
 Inc. (the "Company");

(2) do
 and perform any and all acts for and on behalf of the undersigned that may be necessary or
 desirable to complete and execute any such Form 3, 4, or 5, Schedule 13D, or Schedule 13G,
 or other form or report, and to timely file such form or report with the United States Securities
 and Exchange Commission and any stock exchange or similar authority; and

(3) take
 any other action of any type whatsoever in connection with the foregoing, which, in the opinion
 of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required
 by, the undersigned, it being understood that the documents executed by such attorney-in-fact
 on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and
 shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's
 discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 or Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, or 5, Schedule 13D, or Schedule 13G with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

 

*IN WITNESS WHEREOF*, the undersigned has caused this Power of Attorney to be executed as of September 7, 2022.

---

| | |
|:---|:---|
| | */s/ Nathan Perlmutter* |
|  | Nathan Perlmutter |

---

[Signature Page to Power of Attorney]

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Perlmutter Nathan M<br><sub>(Last) (First) (Middle)</sub><br>28 PARRISH POND LANE<br><sub>(Street)</sub><br>SOUTHAMPTON, NY 11968<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>bioAffinity Technologies, Inc. [ BIAF ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2022-08-29 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock, par value $0.007<sup>(1)</sup> | 166089 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Secured Convertible Promissory Note<sup>(1)</sup> | 2022-09-06 | 2022-10-31 | Common Stock | 31780<sup>(2)</sup> | $4.20 | D |  |
| Secured Convertible Promissory Note<sup>(1)</sup> | 2022-09-06 | 2022-10-31 | Common Stock | 87851<sup>(3)</sup> | $4.20 | D |  |
| Unsecured Convertible Promissory Note<sup>(1)</sup> | 2022-09-06 | 2022-10-31 | Common Stock | 27378<sup>(4)</sup> | $4.20 | D |  |
| Warrants (right to buy)<sup>(1)</sup> | 2022-07-20 | 2027-07-20 | Common Stock | 47935<sup>(5)</sup> | $5.25 | D |  |
| Series A Convertible Preferred Stock<sup>(1)</sup> | 2017-07-11 | <sup>(6)</sup> | Common Stock | 103682 | $6.75 | D |  |

---

### Footnotes:

(1) The number of shares of common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer") and the conversion or exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the Issuer's Common Stock, which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

(2) Represents $133,476.00 of outstanding principal and accrued and unpaid interest of this secured convertible promissory note (a "Note"), dated January 14, 2019, calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 31,780 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.

(3) Represents $368,975.34 of outstanding principal and accrued and unpaid interest of this secured Note, dated October 23, 2019, calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 87,851 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.

(4) Represents $114,991.78 of outstanding principal and accrued and unpaid interest of this unsecured Note, dated October 22, 2020, calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 27,378 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.

(5) Represents a right to purchase an aggregate of 47,935 shares of Common Stock underlying three warrants at an exercise price of $5.25 per share, all of which were issued to Mr. Perlmutter on July 20, 2022.

(6) The Series A Convertible Preferred Stock (the "Preferred Stock") has no expiration date. Immediately prior to the closing of the IPO on September 6, 2022, the Preferred Stock will automatically convert into fully paid and nonassessable shares of Common Stock at the then-effective conversion rate of the Preferred Stock, which is initially 1-for-7 (as adjusted for the Issuer's 1-for-7 reverse stock split).

**Remarks:**
Exhibit List - Exhibit 24.1: Power of Attorney (Nathan Perlmutter)

**Signature:** /s/ Wilhelm E. Liebmann, as attorney-in-fact for Nathan Perlmutter  
**Date:** 2023-03-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**